To Top

Download: Analyzing Trends in Orphan Drugs and Expenditures

Quintiles IMS issued a study which finds that orphan drugs accounted for only 7.9% of total drug sales in the U.S. in 2016. This study, released on October 17, 2017, was commissioned by NORD and analyzed the role of the Orphan Drug Act and orphan drug usage and costs, to address a number of public policy and health care financing issues in the rare disease community.





Click here to download the QuintilesIMS Report titled, “Orphan Drugs in the United States: Providing Context for Use and Cost.”








Click here for NORD’s white paper analyzing the trends in orphan drug costs and expenditures with a background and history on the Orphan Drug Act.